Three-Year data from CheckMate -227 confirm durable, long-term survival benefit for nivolumab plus ipilimumab vs. chemotherapy as first-line treatment of metastatic non-small cell lung cancer patients with PD-L1 ≥1%

With a median follow-up of more than 3 years, the combination continued to show a survival benefit compared to chemotherapy (HR 0.79; 95% CI, 0.67 -0.93) among patients whose tumours expressed PD-L1 ≥1%. Three-year overall survival rates were 33% vs 22%, respectively.


Biospace Inc.